Rifampin drug interactions

A. M. Baciewicz, Timothy Self

Research output: Contribution to journalReview article

73 Citations (Scopus)

Abstract

Rifampin, an antituberculosis agent, is usually administered for nine to 12 months with other antituberculosis drugs or drugs from other classes. A potential for drug interactions often exists because this drug is a potent inducer of drug metabolism. Rifampin causes a proliferation of the smooth endoplasmic reticulum and an increase in the cytochrome P-450 content in the liver. Rifampin's enzyme-induction effect is selective; therefore, it is not always clear which agents will be affected. Studies and case reports have demonstrated that rifampin accelerates the metabolism of several drugs, including oral anticoagulants, oral contraceptives, glucocorticoids, digitoxin, quinidine, methadone, hypoglycemics, and barbiturates. Rifampin interacts with other agents, but further study is needed to demonstrate the clinical importance of these interactions. In addition to inducing drug-metabolizing enzymes, rifampin may cause alterations in absorption and hepatic uptake. Future investigations will probably identify new rifampin drug interactions.

Original languageEnglish (US)
Pages (from-to)1667-1671
Number of pages5
JournalArchives of Internal Medicine
Volume144
Issue number8
DOIs
StatePublished - Jan 1 1984

Fingerprint

Rifampin
Drug Interactions
Pharmaceutical Preparations
Digitoxin
Smooth Endoplasmic Reticulum
Enzyme Induction
Barbiturates
Quinidine
Liver
Methadone
Oral Contraceptives
Hypoglycemic Agents
Anticoagulants
Cytochrome P-450 Enzyme System
Glucocorticoids
Enzymes

All Science Journal Classification (ASJC) codes

  • Internal Medicine

Cite this

Rifampin drug interactions. / Baciewicz, A. M.; Self, Timothy.

In: Archives of Internal Medicine, Vol. 144, No. 8, 01.01.1984, p. 1667-1671.

Research output: Contribution to journalReview article

Baciewicz, AM & Self, T 1984, 'Rifampin drug interactions', Archives of Internal Medicine, vol. 144, no. 8, pp. 1667-1671. https://doi.org/10.1001/archinte.144.8.1667
Baciewicz, A. M. ; Self, Timothy. / Rifampin drug interactions. In: Archives of Internal Medicine. 1984 ; Vol. 144, No. 8. pp. 1667-1671.
@article{0612597ed8264eca9495c179e0b9b020,
title = "Rifampin drug interactions",
abstract = "Rifampin, an antituberculosis agent, is usually administered for nine to 12 months with other antituberculosis drugs or drugs from other classes. A potential for drug interactions often exists because this drug is a potent inducer of drug metabolism. Rifampin causes a proliferation of the smooth endoplasmic reticulum and an increase in the cytochrome P-450 content in the liver. Rifampin's enzyme-induction effect is selective; therefore, it is not always clear which agents will be affected. Studies and case reports have demonstrated that rifampin accelerates the metabolism of several drugs, including oral anticoagulants, oral contraceptives, glucocorticoids, digitoxin, quinidine, methadone, hypoglycemics, and barbiturates. Rifampin interacts with other agents, but further study is needed to demonstrate the clinical importance of these interactions. In addition to inducing drug-metabolizing enzymes, rifampin may cause alterations in absorption and hepatic uptake. Future investigations will probably identify new rifampin drug interactions.",
author = "Baciewicz, {A. M.} and Timothy Self",
year = "1984",
month = "1",
day = "1",
doi = "10.1001/archinte.144.8.1667",
language = "English (US)",
volume = "144",
pages = "1667--1671",
journal = "JAMA Internal Medicine",
issn = "2168-6106",
publisher = "American Medical Association",
number = "8",

}

TY - JOUR

T1 - Rifampin drug interactions

AU - Baciewicz, A. M.

AU - Self, Timothy

PY - 1984/1/1

Y1 - 1984/1/1

N2 - Rifampin, an antituberculosis agent, is usually administered for nine to 12 months with other antituberculosis drugs or drugs from other classes. A potential for drug interactions often exists because this drug is a potent inducer of drug metabolism. Rifampin causes a proliferation of the smooth endoplasmic reticulum and an increase in the cytochrome P-450 content in the liver. Rifampin's enzyme-induction effect is selective; therefore, it is not always clear which agents will be affected. Studies and case reports have demonstrated that rifampin accelerates the metabolism of several drugs, including oral anticoagulants, oral contraceptives, glucocorticoids, digitoxin, quinidine, methadone, hypoglycemics, and barbiturates. Rifampin interacts with other agents, but further study is needed to demonstrate the clinical importance of these interactions. In addition to inducing drug-metabolizing enzymes, rifampin may cause alterations in absorption and hepatic uptake. Future investigations will probably identify new rifampin drug interactions.

AB - Rifampin, an antituberculosis agent, is usually administered for nine to 12 months with other antituberculosis drugs or drugs from other classes. A potential for drug interactions often exists because this drug is a potent inducer of drug metabolism. Rifampin causes a proliferation of the smooth endoplasmic reticulum and an increase in the cytochrome P-450 content in the liver. Rifampin's enzyme-induction effect is selective; therefore, it is not always clear which agents will be affected. Studies and case reports have demonstrated that rifampin accelerates the metabolism of several drugs, including oral anticoagulants, oral contraceptives, glucocorticoids, digitoxin, quinidine, methadone, hypoglycemics, and barbiturates. Rifampin interacts with other agents, but further study is needed to demonstrate the clinical importance of these interactions. In addition to inducing drug-metabolizing enzymes, rifampin may cause alterations in absorption and hepatic uptake. Future investigations will probably identify new rifampin drug interactions.

UR - http://www.scopus.com/inward/record.url?scp=0021219993&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021219993&partnerID=8YFLogxK

U2 - 10.1001/archinte.144.8.1667

DO - 10.1001/archinte.144.8.1667

M3 - Review article

VL - 144

SP - 1667

EP - 1671

JO - JAMA Internal Medicine

JF - JAMA Internal Medicine

SN - 2168-6106

IS - 8

ER -